Cover Image
市場調查報告書

韋格納氏多發性血管炎 : 開發平台分析

Wegener Polyangiitis - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 350597
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
韋格納氏多發性血管炎 : 開發平台分析 Wegener Polyangiitis - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 60 Pages
簡介

韋格納氏多發性血管炎是引起血管發炎的罕見疾病。症候有不斷地流鼻涕和鼻血,耳朵的感染疾病,咳嗽,胸部疼痛,皮膚潰瘍,發燒等。致病因素有年齡等。可使用免疫抑製藥和皮質類固醇加以治療。

本報告提供韋格納氏多發性血管炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新新聞和發表的企業和研究機關正在開發之治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

韋格納氏多發性血管炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

治療藥的開發企業

  • Bionovis SA
  • Bristol-Myers Squibb Company
  • ChemoCentryx, Inc.
  • Coherus BioSciences, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Genor BioPharma Co., Ltd.
  • GlaxoSmithKline Plc
  • Hospira, Inc.
  • Panacea Biotec Limited
  • Sandoz International GmbH
  • The International Biotechnology Center (IBC) Generium

治療藥的評估

  • 單劑產品別
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8201IDB

Summary

Global Markets Direct's, 'Wegener Polyangiitis - Pipeline Review, H1 2016', provides an overview of the Wegener Polyangiitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wegener Polyangiitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wegener Polyangiitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Wegener Polyangiitis
  • The report reviews pipeline therapeutics for Wegener Polyangiitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Wegener Polyangiitis therapeutics and enlists all their major and minor projects
  • The report assesses Wegener Polyangiitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Wegener Polyangiitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Wegener Polyangiitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Wegener Polyangiitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Wegener Polyangiitis Overview
  • Therapeutics Development
    • Pipeline Products for Wegener Polyangiitis - Overview
  • Wegener Polyangiitis - Therapeutics under Development by Companies
  • Wegener Polyangiitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Wegener Polyangiitis - Products under Development by Companies
  • Wegener Polyangiitis - Companies Involved in Therapeutics Development
    • Bionovis SA
    • Bristol-Myers Squibb Company
    • ChemoCentryx, Inc.
    • Coherus BioSciences, Inc.
    • Genor BioPharma Co., Ltd.
    • GlaxoSmithKline Plc
    • Panacea Biotec Limited
    • Sandoz International GmbH
    • The International Biotechnology Center (IBC) Generium
  • Wegener Polyangiitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abatacept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • belimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CCX-168 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Wegener Polyangiitis - Dormant Projects
  • Wegener Polyangiitis - Discontinued Products
  • Wegener Polyangiitis - Product Development Milestones
    • Featured News & Press Releases
      • Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Wegener Polyangiitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Wegener Polyangiitis - Pipeline by Bionovis SA, H1 2016
  • Wegener Polyangiitis - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Wegener Polyangiitis - Pipeline by ChemoCentryx, Inc., H1 2016
  • Wegener Polyangiitis - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Wegener Polyangiitis - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • Wegener Polyangiitis - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Wegener Polyangiitis - Pipeline by Panacea Biotec Limited, H1 2016
  • Wegener Polyangiitis - Pipeline by Sandoz International GmbH, H1 2016
  • Wegener Polyangiitis - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Wegener Polyangiitis - Dormant Projects, H1 2016
  • Wegener Polyangiitis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Wegener Polyangiitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top